---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-084242"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-07-16T20:05:45+00:00"
generated_at: "2026-07-16T20:07:09.932302+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics stockholders approve authorized share increase and reverse split

## Summary
- Authorized common stock increased from 260M to 600M shares via Certificate of Amendment filed July 16, 2026.
- Reverse stock split approved at ratio 1:10 to 1:50, with exact ratio to be set by board of directors.
- Stockholders approved issuance of shares underlying warrants from April 2026 private placement (up to 16.1M shares) and placement agent warrants.
- Special meeting quorum was 51.5% (62.3M of 120.9M outstanding shares present or represented).
- Proposal 2 (authorized share increase) passed with 24.4M for, 8.7M against; Proposal 3 (reverse split) passed with 44.3M for, 17.8M against.

## SEC filing metadata
- accession: 0001104659-26-084242
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-07-16T20:05:45+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926084242/0001104659-26-084242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926084242/tm2620677d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-084242
- JSON: https://secwatch.observer/filing/0001104659-26-084242.json
- Plain text: https://secwatch.observer/filing/0001104659-26-084242.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.